Medtronic plc (MDT) — Fair Value Analysis

Base-case fair value (P50): $77.73 · Current price: $83.19 · Verdict: Fairly Valued

The Verdict on MDT

Based on our Monte Carlo simulations, Medtronic (MDT) is currently considered Fairly Valued. While the current market price of $83.19 trades at an -6.6% discount relative to our median fair value (P50) of $77.73, this difference falls within a range that suggests the stock is neither significantly overvalued nor undervalued at present. Our comprehensive analysis accounts for thousands of potential forward scenarios, anchoring our P50 estimate of $77.73 as the most probable central outcome.

How MDT stacks up against Healthcare

Medtronic operates within the Healthcare sector, a segment often characterized by strong fundamentals. However, our quality tier assessment for MDT indicates a "weak" operational and financial health compared to its sector peers. This "weak" rating may influence why MDT's $83.19 is trading at -6.6% below its P50 fair value of $77.73, suggesting that while the stock is fairly valued, there are underlying operational considerations that could temper its upside potential relative to the sector's stronger players.

What this means for investors

For investors considering MDT, the "Fairly Valued" verdict, coupled with the "weak" quality tier, implies a nuanced outlook. The current price of $83.19 versus the $77.73 median fair value, which represents an -6.6% gap, indicates that the market is largely reflecting Medtronic's current operational reality. While our Monte Carlo model suggests no significant mispricing, the "weak" quality tier flags potential headwinds or less robust financials compared to the broader Healthcare sector. Understanding the full bear-case and bull-case distributions, and the probability of various outcomes, is crucial for a complete picture. Sign up for a free FairCurve account to see the full bear/bull distribution for MDT and track its fair value as new fundamentals are released.